Overview

Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus

Status:
Not yet recruiting

Trial end date:
2024-02-01

Target enrollment:
0

Participant gender:
All

Summary

The purpose of this study is to evaluate the efficacy and safety of Piemonte association in the treatment of type 2 diabetes mellitus

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

EMS

Treatments:

Empagliflozin
Pioglitazone

Criteria

Inclusion Criteria:

- Ability to confirm voluntary participation and agree to all trial purposes by signing
and dating the consent form;

- Diagnosis of type II diabetes mellitus, and who did not reach the therapeutic goal of
HbA1c with previous dietary, physical exercise, and previous therapies at stable doses
within 3 months.

Exclusion Criteria:

- Any clinical and laboratory findings that, in the judgment of the investigator, may
interfere with the safety of participants;

- History of alcohol abuse or illicit drug use;

- Participation in a clinical trial in the year prior to this study;

- Pregnancy or risk of pregnacy and lactating participants;

- Known hypersensitivity to any of the formula compounds;

- Type 1 diabetes.